Gene · 6258
RXRG: retinoid X receptor gamma
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RXRG: retinoid X receptor gamma. Genes, record 6258. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6258
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P48443 | Retinoic acid receptor RXR-gamma | 463 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents57
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 61573 | P48443 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 7761 | P48443 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15594 | P48443 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 7761 | P48443 | Espacenet |
| JP 2025513058 A | 2025-04-22 | 7 | P48443 | Espacenet |
| US 12280021 B2 | 2025-04-22 | 66 | P48443 | Espacenet |
| US 12269793 B2 | 2025-04-08 | 66 | P48443 | Espacenet |
| JP 2025038035 A | 2025-03-18 | 4340 | P48443 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 15594 | P48443 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 15594 | P48443 | Espacenet |
1 to 10 of 57
See all 57 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ACITRETIN | CHEMBL1131 | Retinoid receptor agonist | AGONIST | ChEMBL |
| ALITRETINOIN | CHEMBL705 | Retinoid receptor agonist | AGONIST | ChEMBL |
| BEXAROTENE | CHEMBL1023 | Retinoid X receptor agonist | AGONIST | ChEMBL |
| ETRETINATE | CHEMBL464 | Retinoid receptor agonist | AGONIST | ChEMBL |
| IRX-4204 | CHEMBL75133 | Retinoid X receptor agonist | AGONIST | ChEMBL |
| MOFAROTENE | CHEMBL146506 | Retinoid receptor modulator | MODULATOR | ChEMBL |
Trials80
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06739551 | ACITRETIN | PHASE2 | ClinicalTrials.gov | |
| NCT06723171 | IRX-4204 | PHASE2 | ClinicalTrials.gov | |
| NCT05401006 | ACITRETIN | PHASE4 | ClinicalTrials.gov | |
| NCT05296304 | BEXAROTENE | PHASE1 | ClinicalTrials.gov | |
| NCT05259722 | ALITRETINOIN | PHASE3 | 2025-03-14 | ClinicalTrials.gov |
| NCT05203354 | ACITRETIN | PHASE4 | ClinicalTrials.gov | |
| NCT05184348 | ACITRETIN | PHASE1 | ClinicalTrials.gov | |
| NCT05106192 | BEXAROTENE | ClinicalTrials.gov | ||
| NCT04664829 | BEXAROTENE | PHASE1 | ClinicalTrials.gov | |
| NCT04537689 | ACITRETIN | PHASE4 | ClinicalTrials.gov |
1 to 10 of 80
See all 80 trialsNIH grants813
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RXRG papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA091842 | Cancer Center Support Grant | 3 | 2025 |
| R01CA137124 | Production and progression of premalignant retinoblastoma lesions. | 3 | 2025 |
| R01HL086694 | From GWAS loci to blood pressure genes, variants & mechanisms - Renewal | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 2 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 2 | 2025 |
| P30ES019776 | HERCULES: Exposome Research Center | 2 | 2025 |
| P30EY008126 | Core Grant in Vision Research | 2 | 2025 |
| P50CA171963 | Specialized Program of Research Excellence (SPORE) in Leukemia | 2 | 2025 |
1 to 10 of 813Source NIH's project files
See all 813 nih grantsPapers895
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| In Silico Multitarget Profiling of Betulinic Acid: ADME/Protox-II Toxicity, Network Pharmacology, and Molecular Docking for Diabetic Osteoporosis. | Curr Drug Discov Technol | 2026 | 42634321 | PubTator, text mining | PubMed |
| Integrative single-nucleus transcriptomic analysis identifies UBE2C+ proliferative tumor cells and immune-stromal regulatory crosstalk in small cell lung cancer. | Front Immunol | 2026 | 42614523 | PubTator, text mining | PubMed |
| Psoralen enhances direct cardiac reprogramming via activating PPARα and driving mitochondrial fission and improves cardiac function after myocardial infarction. | Stem Cell Res Ther | 2026 | 42421106 | PubTator, text mining | PubMed |
| Liver endothelial zonation orchestrates hepatic steatosis onset through retinoic acid-regulated FGF1. | Sci Adv | 2026 | 42319926 | PubTator, text mining | PubMed |
| Quadruple immunotherapy with allogeneic natural killer cell infusion for recurrent neuroblastoma. | Cytotherapy | 2026 | 42202757 | PubTator, text mining | PubMed |
| Towards a unified molecular mechanism for ligand-dependent activation of NR4A-RXR heterodimers. | Elife | 2026 | 42059885 | PubTator, text mining | PubMed |
| Epigenetic dichotomy in florid vs. gliotic proliferative diabetic retinopathy: hypomethylation of EGLN1 and MMP9 drives divergent pathogenic pathways in angiogenesis and fibrosis. | Front Endocrinol (Lausanne) | 2026 | 41958874 | PubTator, text mining | PubMed |
| RXR Gamma Enables Oligodendrocyte Differentiation by Suppressing Sonic Hedgehog Signaling. | Glia | 2026 | 41934103 | PubTator, text mining | PubMed |
| Copper deficiency impairs oligodendrocyte maturation and social behavior via mitophagy and mTOR suppression in ASD. | Sci Adv | 2026 | 41920999 | PubTator, text mining | PubMed |
| Deciphering the cardiac neuron landscape in heart failure patients. | PLoS Comput Biol | 2026 | 41860822 | PubTator, text mining | PubMed |
1 to 10 of 895
See all 895 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6258
GET https://conductscience.org/api/genes/v1/6258/patents?page=2